Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors?

被引:129
作者
Zoccali, C [1 ]
机构
[1] CNR, Ctr Fisiol Clin, Div Nefrol & Trapianto Rene, I-89100 Reggio Calabria, Italy
关键词
D O I
10.1093/ndt/15.4.454
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
引用
收藏
页码:454 / 457
页数:4
相关论文
共 18 条
[1]   CARDIOVASCULAR-DISEASE RISK PROFILES [J].
ANDERSON, KM ;
ODELL, PM ;
WILSON, PWF ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298
[2]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]  
COLINS R, 1990, LANCET, V335, P827
[5]  
Coronado B., 1997, JASN, V8, p135A
[6]   CLINICAL AND ECHOCARDIOGRAPHIC DISEASE IN PATIENTS STARTING END-STAGE RENAL-DISEASE THERAPY [J].
FOLEY, RN ;
PARFREY, PS ;
HARNETT, JD ;
KENT, GM ;
MARTIN, CJ ;
MURRAY, DC ;
BARRE, PE .
KIDNEY INTERNATIONAL, 1995, 47 (01) :186-192
[7]   Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1379-1385
[8]   When to base clinical policies on observational versus randomized trial data [J].
Hornberger, J ;
Wrone, E .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (08) :697-703
[9]  
Koch M, 1997, J AM SOC NEPHROL, V8, P1889
[10]   Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start? [J].
Levey, AS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S5-S13